caffeine has been researched along with Disease Exacerbation in 44 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Our previous in vivo studies showed that prenatal caffeine exposure (PCE) could restrain the development of chondrogenesis, which may delay fetal articular cartilage development and increase susceptibility to osteoarthritis in adults." | 7.88 | Prenatal caffeine exprosure increases adult female offspring rat's susceptibility to osteoarthritis via low-functional programming of cartilage IGF-1 with histone acetylation. ( Chen, L; Li, J; Lu, K; Magdalou, J; Ni, Q; Tan, Y; Wang, H; Zhao, Z, 2018) |
| "To estimate the association between long-term caffeine intake and risk of urinary incontinence (UI) progression over 2 years among women with moderate UI." | 7.78 | Caffeine intake and risk of urinary incontinence progression among women. ( Grodstein, F; Resnick, NM; Townsend, MK, 2012) |
| "Coffee and caffeine consumption influence spontaneous conversion of atrial fibrillation." | 7.77 | Influence of coffee and caffeine consumption on atrial fibrillation in hypertensive patients. ( Farinetti, A; Mattioli, AV; Mattioli, G; Miloro, C; Pedrazzi, P, 2011) |
| " We investigated whether CPC implants containing anticancer drugs and caffeine, which enhance the cytocidal effect of anticancer drugs, would enhance their antitumor effects on rat osteosarcomas (SOSN2 cells)." | 7.77 | Potentiation of the antitumor effect of calcium phosphate cement containing anticancer drug and caffeine on rat osteosarcoma. ( Hayashi, K; Kawahara, M; Nishida, H; Shirai, T; Takeuchi, A; Tanzawa, Y; Tomita, K; Tsuchiya, H, 2011) |
| "Although some studies have reported a negative influence of caffeine on bone metabolism, there is no information about its effect on the progression of periodontitis." | 7.74 | Administration of high doses of caffeine increases alveolar bone loss in ligature-induced periodontitis in rats. ( Bastos, MF; Bezerra, JP; da Silva, LR; de Alvarenga Lemos, VA; Duarte, PM, 2008) |
| "The present study investigated the inhibitory effects of Polyphenon E [a standardized green tea polyphenol preparation containing 65% (-)-epigallocatechin-3-gallate] and caffeine on 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK)-induced lung tumor progression from adenoma to adenocarcinoma." | 7.73 | Inhibition of adenoma progression to adenocarcinoma in a 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced lung tumorigenesis model in A/J mice by tea polyphenols and caffeine. ( Hao, X; Liao, J; Lu, G; Reuhl, KR; Yang, CS; Yang, G, 2006) |
| "The pooled OR of advanced liver fibrosis in HCV-infected patients who consumed caffeine on a regular basis versus those who did not was 0." | 6.55 | Impact of caffeine in hepatitis C virus infection: a systematic review and meta-analysis. ( Thongprayoon, C; Ungprasert, P; Wijarnpreecha, K, 2017) |
| " In particular, several cross-sectional and longitudinal population-based studies suggested a protective effect of coffee, tea, and caffeine use against late-life cognitive impairment/decline, although the association was not found in all cognitive domains investigated and there was a lack of a distinct dose-response association, with a stronger effect among women than men." | 6.52 | Coffee, tea, and caffeine consumption and prevention of late-life cognitive decline and dementia: a systematic review. ( Barulli, MR; Bonfiglio, C; Guerra, V; Logroscino, G; Osella, A; Panza, F; Pilotto, A; Sabbà, C; Seripa, D; Solfrizzi, V, 2015) |
| "Myopia is associated with an increased risk of permanent vision loss." | 5.91 | Oral administration of caffeine metabolite 7-methylxanthine is associated with slowed myopia progression in Danish children. ( Cui, D; Guggenheim, J; Ribel-Madsen, S; Trier, K, 2023) |
| "Caffeine treatment augmented A1AR expression on microglia, with ensuing reduction of EAE severity, which was further enhanced by concomitant treatment with the A1AR agonist, adenosine amine congener." | 5.32 | A1 adenosine receptor upregulation and activation attenuates neuroinflammation and demyelination in a model of multiple sclerosis. ( Henry, S; Noorbakhsh, F; Power, C; Schnermann, J; Tsutsui, S; Warren, K; Winston, BW; Yong, VW, 2004) |
| "Potentially remediable risk factors include frequency of migraine attacks, obesity, excessive use of medications containing opioids and barbiturates, caffeine overuse, stressful life events, depression, sleep disorders and cutaneous allodynia." | 4.85 | What predicts the change from episodic to chronic migraine? ( Bigal, ME; Lipton, RB, 2009) |
| "Our previous in vivo studies showed that prenatal caffeine exposure (PCE) could restrain the development of chondrogenesis, which may delay fetal articular cartilage development and increase susceptibility to osteoarthritis in adults." | 3.88 | Prenatal caffeine exprosure increases adult female offspring rat's susceptibility to osteoarthritis via low-functional programming of cartilage IGF-1 with histone acetylation. ( Chen, L; Li, J; Lu, K; Magdalou, J; Ni, Q; Tan, Y; Wang, H; Zhao, Z, 2018) |
| "Caffeine has been proposed, based on in vitro cultured cell studies, to accelerate progression of autosomal dominant polycystic kidney disease (ADPKD) by increasing kidney size." | 3.88 | Relationship between caffeine intake and autosomal dominant polycystic kidney disease progression: a retrospective analysis using the CRISP cohort. ( Bae, KT; Bennett, WM; Chapman, AB; El Ters, M; Harris, PC; Landsittel, DP; Mahnken, JD; McKenzie, KA; Mrug, M; Rahbari-Oskoui, FF; Torres, VE; Yu, ASL, 2018) |
| "To estimate the association between long-term caffeine intake and risk of urinary incontinence (UI) progression over 2 years among women with moderate UI." | 3.78 | Caffeine intake and risk of urinary incontinence progression among women. ( Grodstein, F; Resnick, NM; Townsend, MK, 2012) |
| "Coffee and caffeine consumption influence spontaneous conversion of atrial fibrillation." | 3.77 | Influence of coffee and caffeine consumption on atrial fibrillation in hypertensive patients. ( Farinetti, A; Mattioli, AV; Mattioli, G; Miloro, C; Pedrazzi, P, 2011) |
| " We investigated whether CPC implants containing anticancer drugs and caffeine, which enhance the cytocidal effect of anticancer drugs, would enhance their antitumor effects on rat osteosarcomas (SOSN2 cells)." | 3.77 | Potentiation of the antitumor effect of calcium phosphate cement containing anticancer drug and caffeine on rat osteosarcoma. ( Hayashi, K; Kawahara, M; Nishida, H; Shirai, T; Takeuchi, A; Tanzawa, Y; Tomita, K; Tsuchiya, H, 2011) |
| "Although some studies have reported a negative influence of caffeine on bone metabolism, there is no information about its effect on the progression of periodontitis." | 3.74 | Administration of high doses of caffeine increases alveolar bone loss in ligature-induced periodontitis in rats. ( Bastos, MF; Bezerra, JP; da Silva, LR; de Alvarenga Lemos, VA; Duarte, PM, 2008) |
| "To examine the association between caffeine intake, cognitive decline, and incident dementia in a community-based sample of subjects aged 65 years and over." | 3.74 | The neuroprotective effects of caffeine: a prospective population study (the Three City Study). ( Ancelin, ML; Barberger-Gateau, P; Carrière, I; Dartigues, JF; de Mendonca, A; Portet, F; Ritchie, K; Rouaud, O, 2007) |
| "The present study investigated the inhibitory effects of Polyphenon E [a standardized green tea polyphenol preparation containing 65% (-)-epigallocatechin-3-gallate] and caffeine on 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK)-induced lung tumor progression from adenoma to adenocarcinoma." | 3.73 | Inhibition of adenoma progression to adenocarcinoma in a 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced lung tumorigenesis model in A/J mice by tea polyphenols and caffeine. ( Hao, X; Liao, J; Lu, G; Reuhl, KR; Yang, CS; Yang, G, 2006) |
| "Caffeine intake was related to moderately better cognitive maintenance over 5 years in older women with vascular disorders." | 2.78 | Caffeine and cognitive decline in elderly women at high vascular risk. ( Berr, C; Kang, JH; Ritchie, K; Vercambre, MN, 2013) |
| "The pooled OR of advanced liver fibrosis in HCV-infected patients who consumed caffeine on a regular basis versus those who did not was 0." | 2.55 | Impact of caffeine in hepatitis C virus infection: a systematic review and meta-analysis. ( Thongprayoon, C; Ungprasert, P; Wijarnpreecha, K, 2017) |
| " In particular, several cross-sectional and longitudinal population-based studies suggested a protective effect of coffee, tea, and caffeine use against late-life cognitive impairment/decline, although the association was not found in all cognitive domains investigated and there was a lack of a distinct dose-response association, with a stronger effect among women than men." | 2.52 | Coffee, tea, and caffeine consumption and prevention of late-life cognitive decline and dementia: a systematic review. ( Barulli, MR; Bonfiglio, C; Guerra, V; Logroscino, G; Osella, A; Panza, F; Pilotto, A; Sabbà, C; Seripa, D; Solfrizzi, V, 2015) |
| "In a subgroup, migraine evolves into a more protracted condition (migraine transformation or progression)." | 2.45 | Migraine chronification--concept and risk factors. ( Bigal, M, 2009) |
| "Differential killing of the patient's cancer cells versus normal cells is a necessity for chemotherapy." | 2.43 | Tumor progression--targets for differential therapy. ( Pardee, AB, 2006) |
| "Myopia is associated with an increased risk of permanent vision loss." | 1.91 | Oral administration of caffeine metabolite 7-methylxanthine is associated with slowed myopia progression in Danish children. ( Cui, D; Guggenheim, J; Ribel-Madsen, S; Trier, K, 2023) |
| "Caffeine intake was evaluated by a 7-day food frequency questionnaire, including all the main sources of caffeine." | 1.56 | Caffeine intake influences disease activity and clinical phenotype in systemic lupus erythematosus patients. ( Alessandri, C; Barbati, C; Ceccarelli, F; Cipriano, E; Conti, F; Lucchetti, R; Natalucci, F; Olivieri, G; Orefice, V; Perricone, C; Spinelli, FR; Valesini, G, 2020) |
| "033) continued over time in a dose-response manner." | 1.46 | The Relationship Between Caffeine Intake and Immunological and Virological Markers of HIV Disease Progression in Miami Adult Studies on HIV Cohort. ( Baum, MK; Campa, A; Fleetwood, C; George, F; Khan, H; Li, Y; Liuzzi, JP; Martinez, SS; Ramamoorthy, V; Rubens, M; Stewart, T, 2017) |
| "Caffeine consumption was associated with a reduced accrual of motor and non-motor disability during 4-year follow-up in de novo PD, highlighting the rationale for using adenosine A2A antagonists since the early phases of PD." | 1.43 | Caffeine consumption and the 4-year progression of de novo Parkinson's disease. ( Amboni, M; Barone, P; Erro, R; Longo, K; Moccia, M; Pellecchia, MT; Picillo, M; Vitale, C, 2016) |
| "Caffeine treatment increased the percentage of mitotic tumor cells undergoing apoptosis (lethal mitosis) whereas RW inhibited the increase in interleukin-6 that occurred during the progression of LNCaP tumors from androgen dependence to androgen independence." | 1.38 | Inhibition of progression of androgen-dependent prostate LNCaP tumors to androgen independence in SCID mice by oral caffeine and voluntary exercise. ( Conney, AH; Cui, XX; Huang, MT; Lee, MJ; Lin, Y; Liu, Y; Shih, WJ; Wagner, GC; Yang, CS; Zheng, X, 2012) |
| "Caffeine use seemed to be an important factor for his atrial tachycardia, since his arrhythmia became worse during caffeine load testing and was ameliorated after the cessation of caffeine." | 1.37 | A case of atrial tachycardia sensitive to increased caffeine intake. ( Kinugawa, T; Kurita, T; Nohara, R; Smith, ML, 2011) |
| "Caffeine treatment augmented A1AR expression on microglia, with ensuing reduction of EAE severity, which was further enhanced by concomitant treatment with the A1AR agonist, adenosine amine congener." | 1.32 | A1 adenosine receptor upregulation and activation attenuates neuroinflammation and demyelination in a model of multiple sclerosis. ( Henry, S; Noorbakhsh, F; Power, C; Schnermann, J; Tsutsui, S; Warren, K; Winston, BW; Yong, VW, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (2.27) | 18.2507 |
| 2000's | 10 (22.73) | 29.6817 |
| 2010's | 28 (63.64) | 24.3611 |
| 2020's | 5 (11.36) | 2.80 |
| Authors | Studies |
|---|---|
| Trier, K | 1 |
| Cui, D | 1 |
| Ribel-Madsen, S | 1 |
| Guggenheim, J | 1 |
| Belvisi, D | 1 |
| Pellicciari, R | 1 |
| Fabbrini, G | 1 |
| Tinazzi, M | 1 |
| Berardelli, A | 1 |
| Defazio, G | 1 |
| Hong, CT | 1 |
| Chan, L | 1 |
| Bai, CH | 1 |
| Orefice, V | 1 |
| Ceccarelli, F | 1 |
| Barbati, C | 1 |
| Lucchetti, R | 1 |
| Olivieri, G | 1 |
| Cipriano, E | 1 |
| Natalucci, F | 1 |
| Perricone, C | 1 |
| Spinelli, FR | 1 |
| Alessandri, C | 1 |
| Valesini, G | 1 |
| Conti, F | 1 |
| Sewter, R | 1 |
| Heaney, S | 1 |
| Patterson, A | 1 |
| Simon, DK | 1 |
| Wu, C | 1 |
| Tilley, BC | 1 |
| Lohmann, K | 1 |
| Klein, C | 1 |
| Payami, H | 1 |
| Wills, AM | 1 |
| Aminoff, MJ | 1 |
| Bainbridge, J | 1 |
| Dewey, R | 1 |
| Hauser, RA | 1 |
| Schaake, S | 1 |
| Schneider, JS | 1 |
| Sharma, S | 1 |
| Singer, C | 1 |
| Tanner, CM | 1 |
| Truong, D | 1 |
| Wei, P | 1 |
| Wong, PS | 1 |
| Yang, T | 1 |
| Ramamoorthy, V | 1 |
| Campa, A | 1 |
| Rubens, M | 1 |
| Martinez, SS | 1 |
| Fleetwood, C | 1 |
| Stewart, T | 1 |
| Liuzzi, JP | 1 |
| George, F | 1 |
| Khan, H | 1 |
| Li, Y | 1 |
| Baum, MK | 1 |
| Long, Y | 1 |
| Sanchez-Espiridion, B | 1 |
| Lin, M | 1 |
| White, L | 1 |
| Mishra, L | 1 |
| Raju, GS | 1 |
| Kopetz, S | 1 |
| Eng, C | 1 |
| Hildebrandt, MAT | 1 |
| Chang, DW | 1 |
| Ye, Y | 2 |
| Liang, D | 1 |
| Wu, X | 1 |
| Tan, Y | 1 |
| Lu, K | 1 |
| Li, J | 1 |
| Ni, Q | 1 |
| Zhao, Z | 1 |
| Magdalou, J | 1 |
| Chen, L | 1 |
| Wang, H | 1 |
| Gregg, JR | 1 |
| Lopez, DS | 1 |
| Reichard, C | 1 |
| Zheng, J | 1 |
| Wu, W | 1 |
| Chapin, B | 1 |
| Kim, J | 1 |
| Daniel, CR | 1 |
| Davis, J | 1 |
| McKenzie, KA | 1 |
| El Ters, M | 1 |
| Torres, VE | 1 |
| Harris, PC | 1 |
| Chapman, AB | 1 |
| Mrug, M | 1 |
| Rahbari-Oskoui, FF | 1 |
| Bae, KT | 1 |
| Landsittel, DP | 1 |
| Bennett, WM | 1 |
| Yu, ASL | 1 |
| Mahnken, JD | 1 |
| Paul, KC | 1 |
| Chuang, YH | 1 |
| Shih, IF | 1 |
| Keener, A | 1 |
| Bordelon, Y | 1 |
| Bronstein, JM | 1 |
| Ritz, B | 1 |
| Vercambre, MN | 1 |
| Berr, C | 1 |
| Ritchie, K | 2 |
| Kang, JH | 1 |
| Shim, SG | 1 |
| Jun, DW | 1 |
| Kim, EK | 1 |
| Saeed, WK | 1 |
| Lee, KN | 1 |
| Lee, HL | 1 |
| Lee, OY | 1 |
| Choi, HS | 1 |
| Yoon, BC | 1 |
| Wang, T | 1 |
| Xi, NN | 1 |
| Chen, Y | 1 |
| Shang, XF | 1 |
| Hu, Q | 1 |
| Chen, JF | 1 |
| Zheng, RY | 1 |
| Panza, F | 1 |
| Solfrizzi, V | 1 |
| Barulli, MR | 1 |
| Bonfiglio, C | 1 |
| Guerra, V | 1 |
| Osella, A | 1 |
| Seripa, D | 1 |
| Sabbà, C | 1 |
| Pilotto, A | 1 |
| Logroscino, G | 1 |
| Campbell, KL | 1 |
| Rangan, GK | 1 |
| Lopez-Vargas, P | 1 |
| Tong, A | 1 |
| Beharry, KD | 1 |
| Valencia, GB | 1 |
| Lazzaro, DR | 1 |
| Aranda, JV | 1 |
| Mackow, MJ | 1 |
| Krishnan, B | 1 |
| Bingaman, WE | 1 |
| Najm, IM | 1 |
| Alexopoulos, AV | 1 |
| Nair, DR | 1 |
| Rodenbeck, SD | 1 |
| Zarse, CA | 1 |
| McKenney-Drake, ML | 1 |
| Bruning, RS | 1 |
| Sturek, M | 1 |
| Chen, NX | 1 |
| Moe, SM | 1 |
| Moccia, M | 1 |
| Erro, R | 1 |
| Picillo, M | 1 |
| Vitale, C | 1 |
| Longo, K | 1 |
| Amboni, M | 1 |
| Pellecchia, MT | 1 |
| Barone, P | 1 |
| Wijarnpreecha, K | 1 |
| Thongprayoon, C | 1 |
| Ungprasert, P | 1 |
| Rizek, P | 1 |
| Kumar, N | 1 |
| Bezerra, JP | 1 |
| da Silva, LR | 1 |
| de Alvarenga Lemos, VA | 1 |
| Duarte, PM | 1 |
| Bastos, MF | 1 |
| Nikić, PM | 1 |
| Zidverc-Trajković, J | 1 |
| Andrić, B | 1 |
| Milinković, M | 1 |
| Stojimirović, B | 1 |
| Bigal, ME | 1 |
| Lipton, RB | 2 |
| Scher, AI | 1 |
| Stewart, WF | 1 |
| Bigal, M | 2 |
| Purnak, T | 1 |
| Ozaslan, E | 1 |
| Cognato, GP | 1 |
| Agostinho, PM | 1 |
| Hockemeyer, J | 1 |
| Müller, CE | 1 |
| Souza, DO | 1 |
| Cunha, RA | 1 |
| Mattioli, AV | 1 |
| Farinetti, A | 1 |
| Miloro, C | 1 |
| Pedrazzi, P | 1 |
| Mattioli, G | 1 |
| Cerimele, JM | 1 |
| Stern, AP | 1 |
| Jutras-Aswad, D | 1 |
| Tanzawa, Y | 1 |
| Tsuchiya, H | 1 |
| Shirai, T | 1 |
| Nishida, H | 1 |
| Hayashi, K | 1 |
| Takeuchi, A | 1 |
| Kawahara, M | 1 |
| Tomita, K | 1 |
| Kinugawa, T | 1 |
| Kurita, T | 1 |
| Nohara, R | 1 |
| Smith, ML | 1 |
| Sonsalla, PK | 1 |
| Wong, LY | 1 |
| Harris, SL | 1 |
| Richardson, JR | 1 |
| Khobahy, I | 1 |
| Li, W | 1 |
| Gadad, BS | 1 |
| German, DC | 1 |
| Cao, C | 1 |
| Loewenstein, DA | 1 |
| Lin, X | 1 |
| Zhang, C | 1 |
| Wang, L | 1 |
| Duara, R | 1 |
| Wu, Y | 1 |
| Giannini, A | 1 |
| Bai, G | 1 |
| Cai, J | 1 |
| Greig, M | 1 |
| Schofield, E | 1 |
| Ashok, R | 1 |
| Small, B | 1 |
| Potter, H | 1 |
| Arendash, GW | 1 |
| Townsend, MK | 1 |
| Resnick, NM | 1 |
| Grodstein, F | 1 |
| Zheng, X | 1 |
| Cui, XX | 1 |
| Huang, MT | 1 |
| Liu, Y | 1 |
| Wagner, GC | 1 |
| Lin, Y | 1 |
| Shih, WJ | 1 |
| Lee, MJ | 1 |
| Yang, CS | 2 |
| Conney, AH | 1 |
| Tsutsui, S | 1 |
| Schnermann, J | 1 |
| Noorbakhsh, F | 1 |
| Henry, S | 1 |
| Yong, VW | 1 |
| Winston, BW | 1 |
| Warren, K | 1 |
| Power, C | 1 |
| Pardee, AB | 1 |
| Lu, G | 1 |
| Liao, J | 1 |
| Yang, G | 1 |
| Reuhl, KR | 1 |
| Hao, X | 1 |
| Carrière, I | 1 |
| de Mendonca, A | 1 |
| Portet, F | 1 |
| Dartigues, JF | 1 |
| Rouaud, O | 1 |
| Barberger-Gateau, P | 1 |
| Ancelin, ML | 1 |
| Shrestha, R | 1 |
| McKinley, C | 1 |
| Showalter, R | 1 |
| Wilner, K | 1 |
| Marsano, L | 1 |
| Vivian, B | 1 |
| Everson, GT | 1 |
| Tofovic, SP | 1 |
| Rominski, BR | 1 |
| Bastacky, S | 1 |
| Jackso, EK | 1 |
| Kost, CK | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Reversal of Hepatic Impairment by Achieving Sustained Virologic Response (SVR) With 12 Weeks of Simeprevir(SMV)/Sofosbuvir(SOF)/Ribavirin(RBV) in Patients With Hepatitis C Virus (HCV) Genotype 1 Infection and Early Decompensation of Cirrhosis (MELD 10 or [NCT02455167] | Phase 3 | 9 participants (Actual) | Interventional | 2015-05-31 | Terminated (stopped due to Study stopped due to low accrual and availability of other treatment options) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Liver function as assessed via MELD score. The Model For End-Stage Liver Disease (MELD) score assesses the severity of patient liver disease. Possible scores range from 6 to 40, with higher scores indicating more severe liver disease and a worse outcome. (NCT02455167)
Timeframe: 12 Weeks
| Intervention | score on a scale (Mean) |
|---|---|
| HCV Positive Group | 7.25 |
Liver function as assessed via MELD score. The Model For End-Stage Liver Disease (MELD) score assesses the severity of patient liver disease. Possible scores range from 6 to 40, with higher scores indicating more severe liver disease and a worse outcome. (NCT02455167)
Timeframe: Baseline
| Intervention | score on a scale (Mean) |
|---|---|
| HCV Positive Group | 8 |
"Number of participants who cleared Hepatitis C (HCV) after 12 weeks was collected (HCV RNA level was Not Detected." (NCT02455167)
Timeframe: 12 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| HCV Positive Group | 4 |
10 reviews available for caffeine and Disease Exacerbation
| Article | Year |
|---|---|
Modifiable risk and protective factors in disease development, progression and clinical subtypes of Parkinson's disease: What do prospective studies suggest?
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Caffeine; Disease Progression; Exercise; Humans; L | 2020 |
The Effect of Caffeine on the Risk and Progression of Parkinson's Disease: A Meta-Analysis.
Topics: Caffeine; Coffee; Cohort Studies; Disease Progression; Humans; Levodopa; Parkinson Disease; Proporti | 2020 |
Coffee Consumption and the Progression of NAFLD: A Systematic Review.
Topics: Caffeine; Coffee; Cross-Sectional Studies; Disease Progression; Female; Humans; Liver Cirrhosis; Mal | 2021 |
Coffee, tea, and caffeine consumption and prevention of late-life cognitive decline and dementia: a systematic review.
Topics: Alzheimer Disease; Caffeine; Coffee; Cognition; Cognition Disorders; Cognitive Dysfunction; Dementia | 2015 |
KHA-CARI Autosomal Dominant Polycystic Kidney Disease Guideline: Diet and Lifestyle Management.
Topics: Blood Pressure; Blood Pressure Monitoring, Ambulatory; Caffeine; Diet; Dietary Proteins; Disease Pro | 2015 |
Pharmacologic interventions for the prevention and treatment of retinopathy of prematurity.
Topics: Antioxidants; Caffeine; Combined Modality Therapy; Disease Progression; Early Medical Intervention; | 2016 |
Impact of caffeine in hepatitis C virus infection: a systematic review and meta-analysis.
Topics: Administration, Oral; Beverages; Caffeine; Central Nervous System Stimulants; Chi-Square Distributio | 2017 |
What predicts the change from episodic to chronic migraine?
Topics: Analgesics; Caffeine; Central Nervous System Stimulants; Chronic Disease; Clinical Trials as Topic; | 2009 |
Migraine chronification--concept and risk factors.
Topics: Caffeine; Disease Progression; Humans; Migraine Disorders; Obesity; Risk Factors; Sleep Apnea Syndro | 2009 |
Tumor progression--targets for differential therapy.
Topics: Antineoplastic Agents; Apoptosis; Caffeine; Cell Cycle; Cell Proliferation; Disease Progression; Dru | 2006 |
1 trial available for caffeine and Disease Exacerbation
| Article | Year |
|---|---|
Caffeine and cognitive decline in elderly women at high vascular risk.
Topics: Aged; Aging; Caffeine; Central Nervous System Stimulants; Cerebrovascular Disorders; Cognition; Cogn | 2013 |
33 other studies available for caffeine and Disease Exacerbation
| Article | Year |
|---|---|
Oral administration of caffeine metabolite 7-methylxanthine is associated with slowed myopia progression in Danish children.
Topics: Administration, Oral; Adolescent; Axial Length, Eye; Caffeine; Child; Denmark; Disease Progression; | 2023 |
Caffeine intake influences disease activity and clinical phenotype in systemic lupus erythematosus patients.
Topics: Adult; Caffeine; Coffee; Cross-Sectional Studies; Cytokines; Disease Progression; Drinking Behavior; | 2020 |
Caffeine, creatine, GRIN2A and Parkinson's disease progression.
Topics: Aged; Caffeine; Creatine; Disease Progression; Female; Gene-Environment Interaction; Genetic Predisp | 2017 |
The Relationship Between Caffeine Intake and Immunological and Virological Markers of HIV Disease Progression in Miami Adult Studies on HIV Cohort.
Topics: Adult; Caffeine; CD4 Lymphocyte Count; Disease Progression; Feeding Behavior; Female; HIV Infections | 2017 |
Global and targeted serum metabolic profiling of colorectal cancer progression.
Topics: Adenoma; Adult; Aged; Caffeine; Case-Control Studies; Chromatography, Liquid; Colonic Polyps; Colore | 2017 |
Prenatal caffeine exprosure increases adult female offspring rat's susceptibility to osteoarthritis via low-functional programming of cartilage IGF-1 with histone acetylation.
Topics: Acetylation; Aggrecans; Animals; Caffeine; Cartilage, Articular; Cells, Cultured; Central Nervous Sy | 2018 |
Coffee, Caffeine Metabolism Genotype and Disease Progression in Patients with Localized Prostate Cancer Managed with Active Surveillance.
Topics: Aged; Caffeine; Coffee; Cytochrome P-450 CYP1A2; Disease Progression; Follow-Up Studies; Humans; Mal | 2019 |
Relationship between caffeine intake and autosomal dominant polycystic kidney disease progression: a retrospective analysis using the CRISP cohort.
Topics: Adult; Caffeine; Disease Progression; Female; Glomerular Filtration Rate; Humans; Kaplan-Meier Estim | 2018 |
The association between lifestyle factors and Parkinson's disease progression and mortality.
Topics: Aged; Alcohol Drinking; Caffeine; Coffee; Disease Progression; Exercise; Female; Humans; Life Style; | 2019 |
Caffeine attenuates liver fibrosis via defective adhesion of hepatic stellate cells in cirrhotic model.
Topics: Actins; Animals; Apoptosis; Caffeine; Cell Adhesion; Cell Line; Cell Proliferation; Cyclic AMP; Dise | 2013 |
Chronic caffeine treatment protects against experimental autoimmune encephalomyelitis in mice: therapeutic window and receptor subtype mechanism.
Topics: Animals; Brain; Caffeine; Cytokines; Disease Progression; Encephalomyelitis, Autoimmune, Experimenta | 2014 |
Increased caffeine intake leads to worsening of electrocorticographic epileptiform discharges as recorded with a responsive neurostimulation device.
Topics: Adult; Beverages; Caffeine; Central Nervous System Stimulants; Disease Progression; Drug Resistant E | 2016 |
Intracellular calcium increases in vascular smooth muscle cells with progression of chronic kidney disease in a rat model.
Topics: Animals; Aorta; Caffeine; Calcium; Calcium Gluconate; Cardiovascular Diseases; Cells, Cultured; Dise | 2017 |
Caffeine consumption and the 4-year progression of de novo Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Caffeine; Cohort Studies; Disease Progression; Female; Humans; Kaplan-Me | 2016 |
Restless legs syndrome.
Topics: Anemia; Anticonvulsants; Caffeine; Central Nervous System Depressants; Central Nervous System Stimul | 2017 |
Administration of high doses of caffeine increases alveolar bone loss in ligature-induced periodontitis in rats.
Topics: Alveolar Bone Loss; Alveolar Process; Animals; Caffeine; Central Nervous System Stimulants; Disease | 2008 |
Caffeine-withdrawal headache induced by hemodialysis.
Topics: Caffeine; Central Nervous System Stimulants; Cerebrovascular Circulation; Coffee; Disease Progressio | 2009 |
Patterns of medication use by chronic and episodic headache sufferers in the general population: results from the frequent headache epidemiology study.
Topics: Adolescent; Adult; Aged; Analgesics; Aspirin; Caffeine; Chronic Disease; Disease Progression; Female | 2010 |
Coffee intake and chronic hepatitis C.
Topics: Antiviral Agents; Caffeine; Coffee; Cytochrome P-450 CYP1A2; Disease Progression; Drinking Behavior; | 2009 |
Caffeine and an adenosine A(2A) receptor antagonist prevent memory impairment and synaptotoxicity in adult rats triggered by a convulsive episode in early life.
Topics: Adenosine A2 Receptor Antagonists; Analysis of Variance; Animals; Animals, Newborn; Caffeine; Diseas | 2010 |
Influence of coffee and caffeine consumption on atrial fibrillation in hypertensive patients.
Topics: Adult; Aged; Atrial Fibrillation; Blood Pressure; Caffeine; Coffee; Disease Progression; Electrocard | 2011 |
Psychosis following excessive ingestion of energy drinks in a patient with schizophrenia.
Topics: Adult; Affect; Antipsychotic Agents; Arousal; Beverages; Caffeine; Central Nervous System Stimulants | 2010 |
Potentiation of the antitumor effect of calcium phosphate cement containing anticancer drug and caffeine on rat osteosarcoma.
Topics: Animals; Antineoplastic Agents; Bone Cements; Bone Neoplasms; Caffeine; Calcium Phosphates; Coated M | 2011 |
A case of atrial tachycardia sensitive to increased caffeine intake.
Topics: Adult; Caffeine; Central Nervous System Stimulants; Coffee; Disease Progression; Electrocardiography | 2011 |
Delayed caffeine treatment prevents nigral dopamine neuron loss in a progressive rat model of Parkinson's disease.
Topics: Animals; Caffeine; Cell Count; Disease Models, Animal; Disease Progression; Dopaminergic Neurons; Ma | 2012 |
High Blood caffeine levels in MCI linked to lack of progression to dementia.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Caffeine; Case-Control Studies; Cognition; Cognitive Dys | 2012 |
Caffeine intake and risk of urinary incontinence progression among women.
Topics: Adult; Aged; Aged, 80 and over; Caffeine; Central Nervous System Stimulants; Diet Surveys; Disease P | 2012 |
Inhibition of progression of androgen-dependent prostate LNCaP tumors to androgen independence in SCID mice by oral caffeine and voluntary exercise.
Topics: Administration, Oral; Androgens; Animals; Apoptosis; Caffeine; Caspase 3; Cell Line, Tumor; Disease | 2012 |
A1 adenosine receptor upregulation and activation attenuates neuroinflammation and demyelination in a model of multiple sclerosis.
Topics: Adenosine; Adenosine A1 Receptor Agonists; Animals; Caffeine; Disease Models, Animal; Disease Progre | 2004 |
Inhibition of adenoma progression to adenocarcinoma in a 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced lung tumorigenesis model in A/J mice by tea polyphenols and caffeine.
Topics: Adenocarcinoma; Adenoma; Analysis of Variance; Animals; Caffeine; Catechin; Cell Proliferation; Dise | 2006 |
The neuroprotective effects of caffeine: a prospective population study (the Three City Study).
Topics: Aged; Aged, 80 and over; Agnosia; AIDS Arteritis, Central Nervous System; Amyloid beta-Peptides; Caf | 2007 |
Quantitative liver function tests define the functional severity of liver disease in early-stage cirrhosis.
Topics: Administration, Oral; Adult; Aged; Antipyrine; Caffeine; Cholic Acid; Cholic Acids; Disease Progress | 1997 |
Caffeine augments proteinuria in puromycin-aminonucleoside nephrotic rats.
Topics: Animals; Caffeine; Creatinine; Disease Progression; Drug Synergism; Kidney Cortex; Kidney Failure, C | 2000 |